Strategic Planning | Published:

In-licensing as a business model

Nature Biotechnology volume 20, pages BE36BE39 (2002) | Download Citation

Subjects

Dennis P. Schafer explains how in-licensing drugs can be a strategy for growing a biotechnology startup quickly and cheaply.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Author information

Affiliations

  1. Dennis P. Schafer has started seven biotechnology companies, and currently serves as chief operating officer of Somatocor Pharmaceuticals, Atlanta, GA SchaferDP@aol.com.

    • Dennis P. Schafer

Authors

  1. Search for Dennis P. Schafer in:

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt0602supp-BE36

Further reading